Business Wire

CIRIUM

23.11.2022 09:01:59 CET | Business Wire | Press release

Share
Cirium Launches First Phase of Satellite-Based Aircraft Maintenance Tracking

Cirium has revealed today the aviation industry’s first satellite-based aircraft maintenance tracking feature in its Ascend Profiles module.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221123005132/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cirium's new Ground Events feature shows how Air France redesigned the cabins of all 15 of its Airbus A330 fleet. (Photo: Business Wire)

Its new Ground Events feature enables aircraft and engine manufacturers, maintenance, repair and overhaul service providers, parts suppliers, lessors and insurers to monitor and predict future aircraft maintenance events.

This means businesses can better understand when and where an aircraft last had a maintenance event and forecast its next visit.

It also helps to identify aircraft transitions and define strategies around how and where maintenance and aftermarket budgets are being allocated by operators or owners.

Jeremy Bowen, CEO at Cirium said: “We are innovators and constantly looking to surface new ideas to empower the aviation industry.

“By tracking each Ground Event of an airline’s aircraft, we can identify whether it was for redesigned cabins, new aircraft branding, a maintenance event, or for its return to service.”

The first phase of the new Ground Events feature captures all instances when aircraft spend over seven days on the ground and identifies the aircraft registration, airport, arrival date and time, departure date and time, ground event duration (in days) and aircraft age. For specific airlines the feature showcases the types of maintenance activity and the provider.

The new feature demonstrates the power of combining Cirium’s unrivaled fleets and advanced satellite-based flight tracking data with the MRO locations and MRO relationships data.

In one example, it shows Air France has been redesigning the cabin interiors of all 15 of their Airbus A330 fleet to match the interiors of their A350 aircraft.

This reflects the carrier’s focus on enhancing the passenger experience and benefitted the airline when air travel started to return post the COVID-19 lockdowns. All 15 A330s were ready to return to service with the new interiors installed in July 2020.

Meanwhile, the feature shows how Lufthansa returned five of their Airbus A340s, which were due for retirement, back into service as the pandemic impacted the deliveries of new aircraft.

It further records how the airline partnered with IAC in Dublin to repaint the A340s in the new Lufthansa livery and regular maintenance checks were conducted by Lufthansa Technik Malta, Lufthansa Technik Philippines, and Joramco.

Given the increased demand during the pandemic for the shipment of PPE and the rise of ecommerce, Cirium’s Ground Events data shows how Federal Express (FedEx) were able to maximize their fleet and leverage strong relationships with their maintenance provider. FedEx ramped up their cargo flights, utilizing young aircraft – around one-to-eight years old – and maintained a consistent two-year maintenance cycle.

The Ground Events feature is part of the Ascend Profiles User Interface (UI) which visualizes aircraft intelligence of airline and lessor profiles and provides quick insights around aircraft types, airport locations, OEMs, MROs and more. The is available as an app and works across desktop, mobile and tablet. Find out more.

About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221123005132/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye